VRTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vertex Pharmaceuticals (VRTX) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company's strong financial performance, leadership in cystic fibrosis therapies, robust pipeline, positive analyst sentiment, and patent protections extending into the late 2030s make it a solid investment opportunity.
The MACD is positive and contracting, RSI is neutral at 39.361, and moving averages are converging. The stock is trading near its key support level (S1: 431.809), indicating a potential buying opportunity. However, the pre-market price is slightly down (-0.48%), suggesting minor short-term weakness.
Vertex's leadership in cystic fibrosis therapies with patent protection until the late 2030s ensures strong profitability.
Collaboration with Moderna on mRNA therapies enhances its market position.
FDA approval to expand Trikafta and Alyftrek labels reinforces its biotech leadership.
Record annual revenue of $12 billion in 2025, driven by cystic fibrosis therapies.
Hedge funds are selling, with a 149.17% increase in selling activity last quarter.
No recent congress trading data or insider buying trends to support sentiment.
Slight gross margin decline (-0.08% YoY).
In Q4 2025, Vertex reported revenue growth of 9.55% YoY to $3.19 billion, net income growth of 30.46% YoY to $1.19 billion, and EPS growth of 30.99% YoY to $4.65. These results indicate strong profitability and operational efficiency.
Analysts are overwhelmingly positive on VRTX. Recent upgrades include Morgan Stanley raising the price target to $612, RBC Capital to $543, and Maxim to $575. Analysts highlight Vertex's robust pipeline, potential blockbuster drugs, and diversification beyond cystic fibrosis. The consensus is an Overweight/Buy rating with price targets significantly above the current price.
